Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 190

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4A
Chunk 190
---
 programs or product candidates or grant licenses on terms that may not be favorable
to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce,
or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates
that we would otherwise prefer to develop and market ourselves.

Business Combination

On July 7, 2021, we entered
into the Merger Agreement with HCCC and Merger Sub. Pursuant to the Merger Agreement, Merger Sub merged with and into HCCC, with HCCC
surviving the merger. Upon consummation of the Business Combination and the other transactions contemplated by the Merger Agreement on
March 7, 2022 (the “ Closing Date”), HCCC became our wholly owned subsidiary. In July 2022, we took the necessary actions to
dissolve HCCC.

Basis of presentation

Our financial statements are
prepared in accordance with accounting principles generally accepted in the United States, or U. S. GAAP. Unless otherwise indicated, all
dollar amounts are presented in thousands.

  Operating Results  
 ─────────────────────

Financial Operations Overview

Revenue

To date, we have not generated
any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development
efforts for our Alpha DaRT technology or other product candidates are successful and result in further regulatory approvals and successful
commercialization efforts, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we
will generate revenue from the commercialization and sale of our Alpha DaRT technology or any other product candidates. We may never succeed
in obtaining further regulatory approvals for our Alpha DaRT technology or any of our other product candidates that we may develop in
the future.

Operating Expenses

Our operating expenses since
inception have consisted solely of research and development costs, marketing expenses and general and administrative costs.

Research and development, net

Research and development,
net consist primarily of costs incurred for our research activities, including the development of and pursuit of further regulatory approvals
of our Alpha DaRT technology, which include:

  employee-related expenses, including                                                                                  

  expenses incurred in connection                                                                                                         

  costs of manufacturing our product                                                                                                        

  consulting and professional                           

  facility costs and other allocated                                                                                                         

  registration and maintenance             

We